In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The attraction of magnetic bone implants and adjustable spines

This article was originally published in Clinica

Executive Summary

As the global economic downturn continues, there are signs that companies are scaling back R&D, at least by one measure: the number of patents filed. Figures from the US Patent and Trademark Office (USPTO) suggest that the total number of patents applications is down 7% so far this year.

You may also be interested in...



ResMed Jumps On Board As Nyxoah Raises €25m For Neurostim Apnea Device

The proceeds from the investment will enable Nyxoah to prepare for the IDE pivotal trial of the Genio system in the US, and accelerate market access and commercialization activities in Europe, Australia and New Zealand.

Editor's Note: Tell Us Your Views In Our Customer Survey

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you would like to see in the format of the content or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Knees Boost Zimmer Biomet; Turnaround Continues, But FDA Woes Linger

Zimmer Biomet reported Q4 results that reflected solid progress in the company’s turnaround efforts, with knees leading the charge. But the company is making slower-than-expected progress resolving FDA warning letter issues and faces a new bribery lawsuit in Mexico.

Topics

UsernamePublicRestriction

Register

MT043781

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel